to Baht 0.009 million. 2. The cost of medical treatments when compared to income from medical treatments increased 6.41% due to the cost of medical treatments from CMR went up amount 11.76% from

4.14 million. 2. The cost of medical treatments when compared to income from medical treatments decreased 5.06% due to the cost of medical treatments from CMR went down 9.00% and the cost of medical

from the same period of last year due to loss on forward contract caused by foreign exchange volatility during the Covid-19 pandemic. 1.2 Cost of goods sold and expenses Consolidated financial statements

. The cost of medical treatments when compared to income from medical treatments decreased 5.06% due to the cost of medical treatments from CMR went down 9.00% and the cost of medical treatments in the

from the 1Q19 catalyst turnaround at our EO-EG facility in USA and due to the plummeting MEG margins in Asia although cushioned by the lower cost USGC economics. On the other hand, our Purified EO (PEO

during first half of 2017. However, the increasing in domestic sales push up the total revenue becoming minor decreasing. Cost of goods sold of Q3/17 is increased by 5.86% comparing with Q2/17 and 7.82

Operating results of the Company for the three-month period ended 31 March 2019 and 2018 are as follows: Revenue by segment Revenue Cost Gross Profit For three-month period ended 31 March For three-month

was stagnant, the food sales for Q2’2018 was Baht 1,607 million, increased by Baht 13 million or 0.8% from Q2’2017 mainly from continued store expansion. Cost of Sales Total cost of sales of the company

for loss of production cost which increased comparing to the compensation of Baht 8.19 million of 2nd quarter of year 2018. DEMCO Public Company Limited Details of the costs involving to the WTGs

from compensation for loss of production cost which increased comparing to the compensation of Baht 18.18 million of 3rd quarter of year 2018. DEMCO Public Company Limited Details of the costs involving